ライフサイエンスコーパス: breast cancer patient

1 natures are predictive of survival for human breast cancer patients.

2 utic strategies to improve the prognosis for breast cancer patients.

3 biomarker for a population of chemoresistant breast cancer patients.

4 sion of E. coli LdcC in the feces of stage 1 breast cancer patients.

5 ul variables from transcriptomic profiles of breast cancer patients.

6 ed with MMP9 expression in tumor tissue from breast cancer patients.

7 k of taxane-induced peripheral neuropathy in breast cancer patients.

8 processing approach to analyze biopsies from breast cancer patients.

9 associated with reduced overall survival in breast cancer patients.

10 and higher incidence of brain metastases in breast cancer patients.

11 after chest RT for HL and 4671 first primary breast cancer patients.

12 mal growth factor receptor-2 (HER2)-positive breast cancer patients.

13 MIB-anti-HER2-VHH1 in healthy volunteers and breast cancer patients.

14 ession were correlated with poor survival of breast cancer patients.

15 with that of TWIST1 in human triple-negative breast cancer patients.

16 MA1 correlates with poor overall survival in breast cancer patients.

17 nd correlate with metastatic status in human breast cancer patients.

18 even independent data sets with totally 1079 breast cancer patients.

19 static niche formation and poor prognosis in breast cancer patients.

20 d in cancers and signifies poor prognosis of breast cancer patients.

21 tween Src kinases, paxillin, and survival of breast cancer patients.

22 sidual cancer cells from neoadjuvant-treated breast cancer patients.

23 prognostic marker and therapeutic target in breast cancer patients.

24 monstrate the feasibility of our approach in breast cancer patients.

25 ors have yielded little clinical benefit for breast cancer patients.

26 ignatures for guiding treatment decisions in breast cancer patients.

27 y regimen is still an unmet medical need for breast cancer patients.

28 or (ER) is a target for endocrine therapy in breast cancer patients.

29 PI4K2A play significant prognostic roles in breast cancer patients.

30 ls, and correlates with poor prognosis among breast cancer patients.

31 usting for known prognostic factors in young breast cancer patients.

32 predictive biomarker for clinical outcome of breast cancer patients.

33 tic targets for reducing tumor recurrence in breast cancer patients.

34 both correlate with poor clinical outcome in breast cancer patients.

35 nts and predicts a poor clinical outcome for breast cancer patients.

36 ely used for many years for the treatment of breast cancer patients.

37 nhibitors (PARPi) benefit only a fraction of breast cancer patients.

38 method (81%) on 5,338 TMA images from 1,853 breast cancer patients.

39 independent prognostic factor for metastatic breast cancer patients.

40 the University of Pittsburgh Medical Center breast cancer patients.

41 3 paired primary and metastatic tissues from breast cancer patients.

42 r the testing of HER2 in clinical samples of breast cancer patients.

43 -suppressed gene signature that can stratify breast cancer patients.

44 were associated with better prognosis in all breast cancer patients.

45 ssociates with poor prognosis in ER-positive breast cancer patients.

46 status correlates well with poor survival of breast cancer patients.

47 nt decrease in overall survival in colon and breast cancer patients.

48 roestradiol ((18)F-FES) in ER-positive (ER+) breast cancer patients.

49 C-chemoresistance in PDXs from NAC-resistant breast cancer patients.

50 Bone metastasis is a major health threat to breast cancer patients.

51 es to maximize the benefits of radiation for breast cancer patients.

52 is associated with a poor prognosis in TNBC breast cancer patients.

53 is hemizygously or homozygously lost in some breast cancer patients.

54 h stem cell maintenance and poor survival of breast cancer patients.

55 within the clinical triple-negative group of breast cancer patients.

56 to neoadjuvant anti-HER2 therapy in HER2(+) breast cancer patients.

57 erived from estrogen receptor-positive (ER+) breast cancer patients.

58 M2-7 genes correlated with poor prognosis in breast cancer patients.

59 ore the S100-targeting reagents for treating breast cancer patients.

60 d estimation of overall metastatic burden in breast cancer patients.

61 er chemotherapeutics, in several subtypes of breast cancer patients.

62 /CT was accurate in diagnosing recurrence in breast cancer patients.

63 pression is associated with poor survival in breast cancer patients.

64 h high expression predicts poor prognosis in breast cancer patients.

65 as able to quantify the target analytes from breast cancer patients.

66 inked glycopeptides cell lines acquired from breast cancer patients.

67 ary tumor surgery on mortality in metastatic breast cancer patients.

68 sion and longer progression-free survival of breast cancer patients.

69 as inversely correlated with ErbB2 levels in breast cancer patients.

70 s located within a minor allele expressed by breast cancer patients.

71 rrelates with poor clinical outcome in human breast cancer patients.

72 to identify various sphingolipid species in breast cancer patients.

73 sive molecular subtypes and poor survival in breast cancer patients.

74 correlated with improved overall survival in breast cancer patients.

75 sion is the most important cause of death in breast cancer patients.

76 ant factor in the prognosis and treatment of breast cancer patients.

77 with distant metastasis and poor outcome in breast cancer patients.

78 , were associated with decreased survival of breast cancer patients.

79 inically correlates with brain metastases in breast cancer patients.

80 ostic signatures and therapeutic options for breast cancer patients.

81 ratio is associated with reduced survival of breast cancer patients.

82 n is associated with poor prognosis in ER(-) breast cancer patients.

83 urgical resection of the primary in stage IV breast cancer patients.

84 d to optimize current treatment strategy for breast cancer patients.

85 ed in a prolonged survival among early-stage breast cancer patients.

86 ential therapeutic target for treating obese breast cancer patients.

87 rmonal therapy brings significant benefit to breast cancer patients.

88 tudy, a Danish cohort study of premenopausal breast cancer patients (2002-2011), for which convention

89 l outcome in estrogen receptor (ER)-negative breast cancer patients, a population with limited availa

90 idated our approach in clinical samples from breast cancer patients across estrogen receptor positive

91 r risk in a case-only analysis including 327 breast cancer patients after chest RT for HL and 4671 fi

92 Sox9 is elevated in breast cancer patients after endocrine therapy failure.

93 concentration) and in samples obtained from breast cancer patients after treatment with the drug for

94 MLK3 inhibitor in pan T cells, isolated from breast cancer patients, also increases cytotoxic CD8(+)

95 iation Consortium containing 68,521 invasive breast cancer patients and 54,865 controls.

96 is mechanically-activated calcium pathway in breast cancer patients and by KRas activation reveal sig

97 ed to the presence of dormant tumor cells in breast cancer patients and cancer survivors.

98 5 (HSPA5) is a marker for poor prognosis in breast cancer patients and has an important role in canc

99 e in peripheral blood T cells is impaired in breast cancer patients and is associated with blunted Th

100 ralateral BPE, BPU, and FGT are decreased in breast cancer patients and may potentially serve as imag

101 n analyzed gene expression profiles of human breast cancer patients and patient-derived xenograft (PD

102 also correlates with a high IGFBP3 status in breast cancer patients and predicts a poor clinical outc

103 variants of uncertain significance found in breast cancer patients and provide detailed analysis by

104 ated with disease progression of ER-positive breast cancer patients and resistance to tamoxifen treat

105 acent benign tissue samples from a cohort of breast cancer patients and RNA-sequencing data from The

106 G7 is overexpressed in tumors of a subset of breast cancer patients and that these patients have lowe

107 are associated with poor outcome in younger breast cancer patients and thus emphasize the central ro

108 at strongly correlates with survival in TCGA breast cancer patients and validate these results in thr

109 d for HER2-negative, CEA-positive metastatic breast cancer patients and warrants further research.

110 rvival among ER-positive and triple negative breast cancer patients and was independent of age, tumor

111 ved downregulation of gp130 and IL6Ralpha in breast cancer patients and was independent of plasma IL6

112 9 polymorphisms and response to tamoxifen in breast cancer patients and, consequently, CYP2C19 genoty

113 f two datasets, one simulated and one from a breast cancer patient, and overview all package function

114 selectively enriched in the tumor stroma of breast cancer patients, and depletion of these factors f

115 aromatase inhibitor (AI) therapy in advanced breast cancer patients, and found that circCNOT2 is dete

116 g genetic risk in the general population, in breast cancer patients, and in unaffected family members

117 ehind the immunosuppression commonly seen in breast cancer patients, and may lead to a new strategy t

118 reliable prognostic biomarker in ER positive breast cancer patients, and predictive of preclinical se

119 Because treatments for breast cancer patients are largely designed based on the

120 ofiling data in a retrospective study of 510 breast cancer patients as a test set and 516 breast canc

121 breast cancer patients as a test set and 516 breast cancer patients as an independent validation set.

122 ous study of large collections of samples of breast cancer patients as well as save time and cost whi

123 h predicted clinical outcomes of ER-positive breast cancer patients, as well as breast cancer metasta

124 he best possible treatment options for their breast cancer patients based on actionable, evidence-bas

125 rmine whether survival differed for invasive breast cancer patients based on hormone receptor (HR) st

126 In tumor tissue from breast cancer patients, beta3 was significantly elevated

127 adjacent residue, previously described in a breast cancer patient, both have gain-of-function Rad50

128 h MCT1 and MCT4 in tissue samples from human breast cancer patients, but not healthy breast tissue.

129 standard-of-care for newly diagnosed HER2(+) breast cancer patients, but some patients treated with t

130 uated tumor growth and a better prognosis in breast cancer patients, but the mechanism of this myoglo

131 cal outcome in tamoxifen treated ER-positive breast cancer patients by repressing estrogen signaling

132 antly associated with poorer survival in the breast cancer patient cohort (n = 1441).

133 In a breast cancer patient cohort coupled with in silico anal

134 MA7A/COX-2/FN predicts for poor prognosis in breast cancer patient cohorts.

135 Breast cancer patients commonly present with comorbiditi

136 nd joint up-regulation of Cx43 and ADORA1 in breast cancer patients correlated with decreased relapse

137 ent of personalized treatment strategies for breast cancer patients could be improved by considering

138 Analysis of TCGA breast cancer patient data showed significant correlatio

139 ases, the leading cause of death in advanced breast cancer patients, depend on tumor cell interaction

140 egrative bioinformatics analysis of multiple breast cancer patient-derived gene expression datasets a

141 structure-forming regions (DeltaG4Rs) in 22 breast cancer patient-derived tumor xenograft (PDTX) mod

142 We have created a large collection of breast cancer patient-derived tumor xenografts (PDTXs),

143 D-DIA method to profile the proteomes of two breast cancer patient-derived xenograft (PDX) models, qu

144 mics to profile protein expression across 24 breast cancer patient-derived xenograft (PDX) models.

145 global, glyco-, and phospho-proteomics using breast cancer patient-derived xenograft (PDX) tumor samp

146 A breast cancer patient-derived xenograft showed similar l

147 acquired neratinib resistance in HER2-mutant breast cancer patient-derived xenografts (PDXs) was also

148 We apply clonealign to triple-negative breast cancer patient-derived xenografts and high-grade

149 A significant proportion of breast cancer patients develop bone metastases, but the

150 finally identified 4932 eligible metastatic breast cancer patients diagnosed between 2010-2013, incl

151 r Database we identified 494,801 stage I-III breast cancer patients diagnosed with either IDC alone o

152 ts with other breast tumor subtypes or older breast cancer patients did not seem to benefit effects o

153 independent cohorts of early stage invasive breast cancer patients (discovery n = 1352; validation n

154 Many breast cancer patients do not complete long-term hormona

155 ay significantly increase response rates for breast cancer patients, especially those with HER2 and E

156 s could be used clinically to identify those breast cancer patients expected to have a poor response

157 arkable decrease in relapse-free survival of breast cancer patients expressing high ZEB1 levels in th

158 rerequisite for identifying methods to treat breast cancer patients featuring such mutations.

159 Meta-analysis of breast cancer patients found that high ATP7A expression

160 Here, we show that breast cancer patients frequently have LN metastases tha

161 e frequency of the R337H variant in sporadic breast cancer patients from Parana state, South Brazil,

162 indel is applied to the unmapped reads of 30 breast cancer patients from TCGA.

163 Additionally, we applied INTEGRATE to 62 breast cancer patients from The Cancer Genome Atlas (TCG

164 agent denosumab in premenopausal early-stage breast cancer patients from the Phase-II D-BEYOND clinic

165 Moreover, in breast cancer patients, GPX8 expression significantly co

166 breast cancer patients (<40 y) than in older breast cancer patients (>/=40 y), ruling out the assumpt

167 n unfavorable relapse-free survival (RFS) in breast cancer patients (HR = 1.93, 95%CI: 1.33-2.80, p =

168 Examining FOXA1 in ~5,000 breast cancer patients identifies several hotspot mutati

169 ith worse survival and higher tumor grade in breast cancer patients in multiple patient cohorts.

170 dentified in 189 Northern Finnish hereditary breast cancer patients in parallel sequencing of 796 DDR

171 ysis studies ~7.3 million variants in 84,457 breast cancer patients in relation to breast cancer surv

172 ved peptide vaccines administered to HER2(+) breast cancer patients in the adjuvant setting suggest s

173 cting local recurrence and survival in young breast cancer patients in the Prospective study of Outco

174 Our results on 196 breast cancer patients indicate that cSLIM can provide s

175 proved the clinical outcome of HER2-positive breast cancer patients, innate and acquired resistance r

176 f cells derived from lung adenocarcinoma and breast cancer patients into a multi-scale stoichiometric

177 ssion of the nuclear receptor 4A1 (NR4A1) in breast cancer patients is a prognostic factor for decrea

178 epidermal growth factor receptor 2 (HER2) in breast cancer patients is associated with increased inci

179 djuvant systemic therapy in the treatment of breast cancer patients is increasing beyond the scope of

180 Treatment of stage IV metastatic breast cancer patients is limited to palliative options

181 colonization, and metastasis in mice, and in breast cancer patients, loss of E6AP associates with poo

182 DMR was not significantly higher in younger breast cancer patients (<40 y) than in older breast canc

183 e cells derived from a brain metastasis of a breast cancer patient (MDA-MB-361).

184 new candidate genes, we examined early-onset breast cancer patients negative for BRCA1 and BRCA2 path

185 Mechanisms explaining why the majority of breast cancer patients never develop metastatic outgrowt

186 e-cell whole-genome sequencing data from two breast cancer patients obtained using two different sequ

187 ses occur in approximately 70% of metastatic breast cancer patients, often leading to skeletal injuri

188 n 40 y (<40 y group) with that in a group of breast cancer patients older than 40 y (>/=40 y group).

189 present in the bone marrow of non-metastatic breast cancer patients, only part of which are derived f

190 DNs for those associating with exosomes from breast cancer patients or controls.

191 observed that high serum resistin levels in breast cancer patients positively correlated with tumor

192 Clinically, breast cancer patients possess sCLU expression only in m

193 fit for surgical resection of the primary in breast cancer patients presenting with de novo stage IV

194 In breast cancer patients, PREX1 levels are significantly i

195 r a role of immune components in influencing breast cancer patients' prognosis.

196 gical procedure performed, demonstrates that breast cancer patients receiving neoadjuvant chemotherap

197 Approximately 30% of ERalpha breast cancer patients relapse with metastatic disease f

198 dividual S100, especially the mRNA level, in breast cancer patients remain elusive.

199 We included 752 operable stage I-III breast cancer patients representing all subtypes treated

200 lysis of available molecular data from >3000 breast cancer patients revealed a dysregulation of the E

201 tochemical staining of samples obtained from breast cancer patients revealed a strong positive correl

202 RNA sequencing of freshly isolated CTCs from breast cancer patients revealed a subset with strong rib

203 High DDX3 expression was present in 35% of breast cancer patient samples and correlated with marker

204 proof-of-principle, we apply MutSpace to 560 breast cancer patient samples and demonstrate that our m

205 otransduction occurs independently of YAP in breast cancer patient samples and mechanically tunable 3

206 Importantly, this mechanism is manifested in breast cancer patient samples and TCGA database, which s

207 les successful scRNA-seq of 666 CTCs from 21 breast cancer patient samples at high throughput.

208 Consistently, breast cancer patient samples portrayed a strong and sig

209 32 non-small cell lung cancer (NSCLC) and 22 breast cancer patient samples, yielding 60 to 100% of th

210 are evident in xenografts in mice and human breast cancer patient samples.

211 enomic similarities to basal-like metastatic breast cancer patient samples.

212 expression at the protein and RNA levels in breast cancer patient samples.

213 ween breast cancer cell lines and metastatic breast cancer patient samples.

214 a tissue microarray with 149 non-metastatic breast cancer patient samples.

215 m)Tc-tilmanocept in a heterogeneous group of breast cancer patients scheduled for SLN biopsy.

216 from human oestrogen receptor (ER)-negative breast cancer patients showed a strong correlation betwe

217 This phase II study with ER+ breast cancer patients showed that (18)F-4FMFES PET achi

218 with SUV(max) and SUV(mean) Methods: Twelve breast cancer patients starting endocrine treatment for

219 formance assessment in anticipation of human breast cancer patient studies.

220 overall response to immunotherapy is low in breast cancer patients, suggesting that effective strate

221 reduced relapse-free and overall survival in breast cancer patients, suggesting that modulation of ER

222 d the alternative splicing of CLSTN1 predict breast cancer patient survival.

223 ways leads to markedly better predictions of breast cancer patients' survival in an independent cohor

224 f these data, we conclude that HER2-positive breast cancer patients that have been treated with trast

225 Forty-eight breast cancer patients that met the clinical criteria fo

226 development of new treatment approaches for breast cancer patients that minimize adverse effects on

227 To accommodate future needs of breast cancer patients, the companion diagnostic model w

228 Among breast cancer patients, those diagnosed with the triple-

229 monitor pathological response and outcome of breast cancer patients to chemotherapy early following t

230 e-wide CRISPR activation screen in CTCs from breast cancer patients to identify genes that promote di

231 tly increase the resistance of HER2-positive breast cancer patients to trastuzumab.

232 as a potential biomarker for the response of breast cancer patients to Vinca alkaloid drug treatment.

233 d to classify the hormone receptor status of breast cancer patients treated at the University of Kans

234 se rate of epigenetic priming in ER-positive breast cancer patients treated with checkpoint inhibitor

235 tes and CTRCD in a prospective cohort of 170 breast cancer patients treated with doxorubicin with or

236 of 102 postmenopausal, HR + HER2- metastatic breast cancer patients treated with everolimus-exemestan

237 In node-positive breast cancer patients treated with neoadjuvant chemothe

238 ACOSOG Z1071 enrolled cT0-4N1-2 breast cancer patients treated with neoadjuvant chemothe

239 Breast cancer patients treated with tamoxifen may experi

240 del to predict tumor response for two HER2 + breast cancer patients treated with the same therapeutic

241 Current study included metastatic HER2+ breast cancer patients treated with trastuzumab (n = 40)

242 validation n = 1655), and 112 HER2 positive breast cancer patients treated with trastuzumab and adju

243 Participants included 5569 early-stage breast cancer patients, treated with breast-conserving s

244 ine protease activities was characterized in breast cancer patient tumor samples.

245 8-week HIIT intervention influences MMP-9 in breast cancer patients undergoing anthracycline chemothe

246 In breast cancer patients undergoing doxorubicin therapy, e

247 s remain a potentially preventable event for breast cancer patients undergoing mastectomy.

248 Breast cancer patients undergoing more extensive axillar

249 early prediction of pathological response in breast cancer patients undergoing neoadjuvant chemothera

250 entially enriched, in the circulating EVs of breast cancer patients undergoing neoadjuvant chemothera

251 rate of positive margins and re-excision in breast cancer patients undergoing partial mastectomy (PM

252 enters across the United States, stage 0-III breast cancer patients undergoing PM were randomly assig

253 e feasibility of imaging tumor metabolism in breast cancer patients using (13)C magnetic resonance sp

254 Breast cancer patients using aromatase inhibitors (AIs)

255 monal and HER2 receptor status phenotypes of breast cancer patients using gene expression profiles.

256 -derived tumor and normal organoids from two breast cancer patients using Illumina/10x Genomics, Paci

257 Early stage breast cancer patients, versus control women, had reduce

258 e, we report that a high expression of AR in breast cancer patients was associated with shorter overa

259 low MCPIP1 expression in tumor samples from breast cancer patients was strongly associated with poor

260 In a cohort of 1,596 breast cancer patients, we analyzed the associations of

261 ndependent multicenter randomized cohorts of breast cancer patients, we identified 17 genes that are

262 In this cohort, 12.5% of the BRCA-negative breast cancer patients were found to carry a known patho

263 Metastatic breast cancer patients were identified in the SEER regis

264 1 and 2015, 90 previously untreated stage IV breast cancer patients were randomly assigned to surgica

265 Treatment-naive breast cancer patients were recruited: four triple-negat

266 Annual mortality rates among breast cancer patients were significantly greater in LMI

267 positively correlated in tissue samples from breast cancer patients, where high expression of both BC

268 unfavorable prognostic value in a cohort of breast cancer patients, where it predicted high probabil

269 significantly poorer survival of stomach and breast cancer patients, whereas an unbalanced Th1/Th2 re

270 els of STYX and FBXW7 are anti-correlated in breast cancer patients, which affects disease prognosis.

271 entified in CHEK2, MUTYH, and RAD51B in four breast cancer patients, which represented 8.3% of the co

272 ssociated with better overall survival among breast cancer patients, while high fruit juice consumpti

273 laboratory tests is powerful in identifying breast cancer patients who are at high risk of recurrenc

274 mune signature in PD-L1-negative ER-positive breast cancer patients who are more likely to benefit fr

275 a collection of gene expression datasets on breast cancer patients who received neoadjuvant chemothe

276 Importantly, breast cancer patients who responded to letrozole expres

277 , representing novel therapeutic targets for breast cancer patients who smoke.

278 PTX/CBP regimen neoadjuvant chemotherapy in breast cancer patients, who also tend to achieve patholo

279 ister Study, a US cohort study of sisters of breast cancer patients, who provided samples at baseline

280 Importantly, breast cancer patients whose tumors express both low str

281 h BCBM.Characterization of CTCs derived from breast cancer patients with brain metastasis (BCBM) may

282 inhibitors may provide improved outcomes for breast cancer patients with drug-resistant metastatic di

283 for exploring the possibility that sporadic breast cancer patients with EMSY amplification might ben

284 ertuzumab) prolong survival in HER2-positive breast cancer patients with extracranial metastases.

285 ins, including the essentiality of MAD2L1 in breast cancer patients with high BRCA-pathway activity.

286 tisera recognize cancer cells in biopsies of breast cancer patients with high selectivity.

287 riple negative breast cancer (TNBC) and 1365 breast cancer patients with information on neoadjuvant c

288 LumA, and LumB breast cancer subtypes of 512 breast cancer patients with invasive ductal carcinoma (I

289 Here, we report that breast cancer patients with low MFN2 expression are asso

290 The gene expression profile of luminal-type breast cancer patients with low RB expression revealed h

291 might be a potential effective treatment for breast cancer patients with metastatic disease.

292 peutics may be effective in the treatment of breast cancer patients with PIK3R1 loss.

293 A total of 23,168 breast cancer patients with positive hormone receptor (H

294 the association between PMRT and outcomes in breast cancer patients with T1-2 tumors and 1-3 positive

295 tudy is to evaluate oncological outcomes for breast cancer patients with T1-2 tumors and 1-3 positive

296 While breast cancer patients with tumors that express estrogen

297 ediately using Hsp90 to improve outcomes for breast cancer patients without affecting traditional car

298 ast cancer survivors and whether it benefits breast cancer patients without diabetes.

299 n obesity-related cytokine-is upregulated in breast cancer patients, yet its impact on breast cancer

300 R) on initial (18)F-FDG PET/CT in a group of breast cancer patients younger than 40 y (<40 y group) w